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Abstract: Programs for quality assurance are increasingly important in surgical pathology. Many quality assurance (QA) 
techniques for surgical pathology were adopted from procedures introduced in cytopathology. Surgical pathology specimens 
have diminished in size such that the majority of diagnostic biopsies of prostatic lesions are now core needle biopsies. These 
specimens raise issues similar to those of cytology specimens, including concerns regarding adequacy and the representative 
nature of the biopsy. Due to sample size, some neoplasms may not be diagnosed on initial biopsy, raising concerns regard-
ing false negative results. Cytopathologists have instituted QA procedures including review of all previously negative slides 
received within ﬁ  ve years prior to the new diagnosis of high grade squamous intraepithelial lesion or gynecologic malig-
nancy. No such requirement exists in surgical pathology for review of core biopsies.
The Department of Pathology at the University of Utah instituted a QA policy requiring review of prior negative prostatic 
needle biopsies following a new diagnosis of prostatic adenocarcinoma. We reviewed ﬁ  ve years of QA records of prostate 
needle biopsy review. During this time, nine hundred and ﬁ  fty-eight core biopsy sets were performed. Two hundred and 
ninety-ﬁ  ve of these contained at least one biopsy with a diagnosis of adenocarcinoma. Two hundred and eight patients had 
a prior set of prostatic needle biopsies with a diagnosis of adenocarcinoma. The remaining 87 had prior biopsies with either 
a diagnosis of prostatic intraepithelial neoplasia (23), small atypical acinar proliferation (21) or no evidence of malignancy 
(43). QA review of these 87 cases revealed two biopsies which revealed foci of adenocarcinoma. Both had been initially 
diagnosed as no evidence of malignancy. The false negative rate for core biopsy was 0.68%. In an additional twenty-one 
cases, microscopic foci of atypical small acinar proliferations were found in core biopsies antedating the positive core 
biopsy (7.1%).
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Introduction
Quality assurance programs have become an important component of laboratory management in 
Anatomic Pathology. Quality assurance and control programs have long been used for assessment 
of the technical components of Anatomic Pathology practice. These procedures have only more 
recently become widely utilized for assessment of the interpretive portion of Anatomic Pathology 
practice. Quality assurance programs have varied widely in their scope, ranging from mandatory 
100% review of Surgical Pathology diagnoses,
16 to more limited programs such as histologic review 
of materials obtained from patients referred to tertiary centers for a second opinion or deﬁ  nitive 
therapy.
3,5 These reviews have documented a small but signiﬁ  cant false positive and false negative 
rate for many specimen types. Epstein et al.
3 demonstrated the value of second opinion review of 
outside materials before deﬁ  nitive therapy. Others have conﬁ  rmed the value of second opinion 
consultation programs.
8,9,12–15
Many institutions, including the University of Utah, have quality assurance programs which randomly 
review approximately 10% of all Surgical Pathology cases and require conﬁ  rmation by a second 
pathologist of all malignant diagnoses. The 100% review format allows identiﬁ  cation of diagnostic 
trends among pathologists and allows retrospective institution of training programs and procedures 
when trends in diagnostic errors are uncovered. One hundred percent prospective review of surgical 78
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pathology cases is costly and may prolong turn-
around time.
10,11 The method of outside slide 
review improves the overall predictive value of a 
positive diagnosis, but reviews only a small per-
centage of cases and will detect predominantly 
false positive diagnoses.
Cytopathologists have often taken the lead in 
developing QA/QC programs in Anatomic Pathol-
ogy. One innovation originating from cytopathol-
ogy is the retrospective review of prior cytologic 
specimens when a new positive diagnosis of high 
grade dysplasia (cervical intraepithelial neoplasia) 
is made. The College of American Pathologists, in 
their inspection protocol requires that cytology 
laboratories review all prior negative cervical 
cytologies over a ﬁ  ve year period after a new diag-
nosis of high-grade squamous intraepithelial lesion 
is made, or a malignant gynecologic case is 
reported. No similar requirement is currently in 
effect for Surgical Pathology specimens. Because 
increasing numbers of breast and prostatic lesions 
are ﬁ  rst investigated by core-needle biopsy, a 
similar program might be of value. Core-needle 
biopsies raise similar issues of sampling and inter-
pretation of limited material as are experienced 
with cytologic specimens. We chose to review 
prostate core biopsies because they are frequently 
repeated when initial biopsies are negative and the 
serum prostatic speciﬁ  c antigen remains elevated. 
To determine the effectiveness of such a program 
in uncovering prior false negative diagnoses, we 
reviewed our ﬁ  ve year experience of prostatic core-
needle biopsies. Herein we report the results of that 
review.
Materials and Methods
The quality assurance records recording the results 
of the prostate core-needle biopsy review program 
at the University of Utah Department of Pathology 
between September 2001 and September 2006 
were reviewed. During that period, 958 core-
needle biopsy sets (six biopsies each) were per-
formed. Two hundred and ninety-ﬁ  ve of these 
biopsy sets had at least one specimen with a diag-
nosis of adenocarcinoma and had prior prostate 
core-needle biopsies. The remaining 663 sets of 
prostate core needle biopsies either had benign 
diagnoses or had no prior core needle biopsies. 
In the QA program, every new diagnosis of 
adenocarcinoma of the prostate identiﬁ  ed on core 
biopsy was automatically ﬂ  agged and a computer 
search for all prior needle biopsies of the prostate 
for that patient was performed. The slides from the 
previous core biopsies were obtained and reviewed 
by a senior surgical pathologist. When necessary, 
immunohistochemistry for CK903 and CK5/6 was 
performed. The original and reviewed diagnoses 
for each of the prior biopsies were recorded along 
with the size and Gleason score of the carcinoma 
when present. The name of the pathologist review-
ing the prior core biopsy was recorded. While a 
urologic oncology conference is held biweekly, 
only positive for malignancy prostate cases are 
presented and routinely reviewed by a second 
pathologist. Repeat sets of core needle biopsies 
were performed due to a “watchful waiting” pro-
tocol (prior positive biopsies) or because of a 
persistently elevated serum prostatic speciﬁ  c anti-
gen level.
Immunohistochemistry for CK5/6 and K903 
was performed on one case at the time of second 
review. The antibodies for CK5/6 were obtained 
from Chemicon (Temecula, CA) and the antibody 
was used at a dilution of 1:400. The antibody for 
K903 was supplied by Enzo (Farmingdale, NY) 
and applied at a dilution of 1:40. In all cases, biop-
sies were formalin ﬁ  xed and parafﬁ  n embedded. 
The diagnostic biopsies were cut at 4 microns and 
stained with hematoxalin and eosin.
Results
Between September 2001 and September 2006, 
nine hundred and ﬁ  fty-eight core-needle biopsy sets 
(six biopsies each) were examined pathologically. 
Two hundred and ninety-ﬁ  ve of these sets of pros-
tatic biopsies contained at least one core biopsy 
associated with a diagnosis of adenocarcinoma. 
Two hundred and eight of these patients had had a 
prior prostatic core needle biopsy where a diagno-
sis of adenocarcinoma had been made. The remain-
ing eighty-seven patients had prior sets of biopsies 
in which at least one biopsy had a diagnosis of 
prostatic intraepithelial neoplasia (PIN) 
(23 patients), small acinar proliferation suspicious 
for carcinoma (21 patients) or no evidence of malig-
nancy (43 patients). Review of the material from 
these eighty seven patients reveal two biopsies in 
which needle-core sections revealed diagnostic foci 
of adenocarcinoma of the prostate. In both cases, 
the foci of adenocarcinoma were microscopic foci 
representing less than 5% of core biopsy volume. 
Both cases were Gleason score 3+3, both in the new 79
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index biopsy and the focus discovered on second 
review (Fig. 1). Immunohistochemistry performed 
at the time of second review demonstrated an 
absence of basal cells in the atypical proliferation 
(Fig. 2). Both cases in which the underdiagnosis 
had been made, had initially been diagnosed as 
showing no evidence of malignancy. At the time of 
the initial false negative core biopsies, the two 
patients had serum prostatic speciﬁ  c antigen levels 
of 10.0 ng/ml and 4.4 ng/ml respectively. In this 
review series, the false negative rate for core-needle 
biopsy of the prostate was 0.68%. Both false nega-
tive diagnoses had been rendered by junior mem-
bers of the division of Anatomic Pathology. 
Following the diagnosis of adenocarcinoma, both 
patients have had at least one additional prostatic 
needle biopsy showing Gleason score 3+3 adeno-
carcinoma. Neither patient had been treated by 
radiation or radical prostectomy. The treating sur-
geon was notiﬁ  ed of the prior false negative diag-
nosis in both cases. In an additional 21 patients, 
original biopsies had shown microscopic collec-
tions of atypical small acinar proliferations (7.1%). 
Review of the original biopsy material in these 21 
cases showed the atypical foci disappeared on 
deeper levels precluding the use of immunohisto-
chemistry for the demonstration of the presence or 
absence of basal cells.
Discussion
Error reduction has become an increasingly impor-
tant concern in medical practice. Adequacy of 
programs for quality control and assurance has 
become an important issue in diagnostic surgical 
pathology with additional procedures and programs 
being encouraged or mandated by societal or 
government leaders. Numerous studies have 
shown a signiﬁ  cant error rate in diagnostic surgi-
cal pathology both between referring and consul-
tant pathologists and among consultant experts.
2,4,6,7 
Reported diagnostic error rates associated with 
review procedures have varied substantially. 
Epstein et al.
3 reported that 1.3% of outside needle 
biopsies had been incorrectly diagnosed as malig-
nant. Weydert et al.
16 reported a “major discrepancy 
rate” of 0.29% between preliminary diagnosis and 
ﬁ  nal staff pathologist diagnosis in a prospective 
blinded dual review system for general surgical 
pathology. In a study by Abt et al.,
1 5.5% of all 
diagnoses showed a therapeutically signiﬁ  cant 
discrepancy between a referring institution and 
the pathology opinion of the treating institution. 
Similarly high discrepancy rates between consul-
tant and referring pathologists have been reported 
by others.
2,4,6,7 From the point of diagnostic accu-
racy and patient care, a prospective peer review 
system in surgical pathology as described by 
Weydert et al.
16 would appear optimal. However, 
issues concerning turn-around time and costs 
mitigate against the universal acceptance of such 
a policy.
10,11 Interinstitutional reviews as described 
by Abt
1 and Epstein
3 are of value when patients 
are initially seen at one institution but treated at a 
second. However, such programs would probably 
impact a minority of operative patients. Most other 
QA systems are retrospective and would not be 
expected to immediately impact the care of the 
patient whose material was undergoing review. 
These retrospective systems, however, are of value 
in that they are useful for documenting diagnostic 
problems for both individual and groups of 
pathologists. The systems can lead to modiﬁ  cation 
of practice patterns and focus of continuing 
education programs. Many institutions perform a 
retrospective review of ten percent of all Surgical 
Figure 1A. Photomicrograph showing small focus of adenocarcinoma 
missed at the time of initial diagnosis (H and E).
Figure 1B. High power view of adenocarcinoma (H and E).80
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Pathology cases. This system, when random, may 
be slow to document trends in diagnostic errors 
in uncommon specimens. When case selection is 
left to the reviewing pathologists, the tendency to 
select small, easily reviewable specimens may 
hinder the effectiveness of the review process in 
discovering errors in complex or diagnostically 
difﬁ  cult lesions. An alternative technique is to 
focus on speciﬁ  c specimen types where diagnos-
tic errors could have high clinical impact. This 
focus has been taken by cytopathologists and the 
College of American Pathologists in their require-
ment for review of prior negative specimens 
whenever a new diagnosis of high grade dysplasia 
or gynecologic malignancy is made on a cervical 
cytology. This approach has the advantage of 
focusing on diagnostically difﬁ  cult areas where 
false negative diagnoses could have signiﬁ  cant 
clinical impact.
The ﬁ  ve year look-back technique used in gyne-
cologic cytology was applied to prostate core-
needle biopsies at the University of Utah. Prostate 
core-needle biopsies were selected for review 
because of their signiﬁ  cant clinical impact when 
incorrectly read as negative. The small size of the 
biopsies also makes diagnostic errors more likely 
than when larger specimens are reviewed. In the 
past two decades, a majority of prostatic and breast 
lesions have been investigated by core-needle 
biopsy. These core-needle biopsies are of relatively 
small gauge and their interpretation raises issues 
similar to those seen in cervical cytology. Issues 
for these small biopsies include the representative 
nature of the sample and whether or not it contains 
an adequate amount of pathologic material to allow 
deﬁ  nitive diagnosis. The QA records of the prostate 
core-needle biopsy ﬁ  ve year retrospective review 
at the University of Utah demonstrated a 0.68% 
false negative rate for interpretation of core-needle 
biopsies. This rate did not include sampling errors, 
but simply reﬂ  ected interpretive errors. Both false 
negative diagnoses were associated with micro-
scopic foci of Gleason score 3 + 3 adenocarcinoma. 
The foci in both patients represented no more than 
5% of the original core-needle biopsy volume. In 
both cases, the false negative diagnosis had been 
rendered by a junior member of the division of 
Anatomic Pathology. While immunohistochemis-
try for CK5,6 and K903 were used to conﬁ  rm the 
presence of adenocarcinoma in the retrospective 
review process, the senior pathologists performing 
the review did not require immunohistochemistry 
for deﬁ  nitive diagnosis.
In an additional twenty-one cases, microscopic 
foci of atypical small acinar proliferations were 
found in core-needle biopsies antedating the diag-
nostically positive core biopsy. Review of these 
21 cases conﬁ  rmed the presence of small atypical 
acinar structures which did not fulﬁ  ll stringent 
diagnostic criteria for adenocarcinoma. In approx-
imately half of these cases, a basal cell layer was 
demonstrable by immunohistochemistry in the 
acinar proliferation. This basal cell layer was usu-
ally non-continuous, but its presence dissuaded the 
review pathologist from rendering a deﬁ  nitive 
diagnosis of adenocarcinoma. In 23 cases, only 
high grade prostatic intraepithelial neoplasia was 
detected, and even at subsequent review, knowing 
that the patient had biopsy proven adenocarcinoma, 
a deﬁ  nitive diagnosis of adenocarcinoma could not 
be made by the senior review pathologist.
The ﬁ  ve year retrospective review program at 
the University of Utah demonstrated a false nega-
tive interpretive rate of approximately 0.68%. This 
is higher than the 0.29% clinical major discrepancy 
rate reported by Weydert et al.
16 In that study, the 
precise number of prostate biopsies was not given, 
but three of the eighteen major discrepancies 
involved prostate biopsies or TURP specimens. 
Two of the errors reported by Weydert et al. were 
underdiagnoses of adenocarcinoma by the initial 
hot seat fellow. Thus our five year look-back 
review and Weydert et al.’s prospective review 
both demonstrating a signiﬁ  cant false negative rate 
for interpretation of prostatic biopsy specimens. 
Epstein’s report of a 1.3% false positive rate in 
prostate core-needle biopsy specimens indicates 
that prostatic needle-core biopsies are difﬁ  cult to 
interpret and may represent a specimen type 
requiring additional review before ﬁ  nal sign-out. 
Figure 2. Immunohistochemical staining for CK5/6 demonstrating 
an absence of basal cells in the focus of adenocarcinoma.81
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By itself, the retrospective review process yields 
valuable information useful for resident teaching, 
continuing medical education, and the monitoring 
of practice patterns in pathology groups.
The discovery of a prior false negative diagno-
sis during QA review raises legal and ethical issues 
including the need to inform the treating physician 
and patient. Given the current medicolegal climate, 
many pathologists may be reticent to undertake 
QA programs likely to uncover false negative 
diagnoses, as such cases might result in delay of 
diagnosis lawsuits. Recent public policy initiatives 
have been developed with an emphasis on a “guilt 
free environment” to facilitate the recognition of 
and reduction in the number of medical errors. QA 
programs such as the one described here may ﬁ  nd 
increased utility for the recognition of medical 
errors by the QA process if the medico-legal envi-
ronment allows a truly “guilt free” approach.
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